Citigroup Inc Catalyst Pharmaceuticals, Inc. Transaction History
Citigroup Inc
- $169 Billion
- Q3 2024
A detailed history of Citigroup Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 155,494 shares of CPRX stock, worth $3.45 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
155,494
Previous 115,111
35.08%
Holding current value
$3.45 Million
Previous $1.78 Million
73.36%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CPRX
# of Institutions
327Shares Held
94.1MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$415 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$178 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$138 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$126 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$67 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.28B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...